Abstract
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.
Original language | English |
---|---|
Pages (from-to) | 244-328 |
Number of pages | 85 |
Journal | World Journal of Biological Psychiatry |
Volume | 19 |
Issue number | 4 |
DOIs | |
State | Published - 19 May 2018 |
Keywords
- Alzheimer’s disease
- biomarkers
- cerebrospinal fluid
- consensus
- dementia
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: World Journal of Biological Psychiatry, Vol. 19, No. 4, 19.05.2018, p. 244-328.
Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias
T2 - An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
AU - on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut
AU - Lewczuk, Piotr
AU - Riederer, Peter
AU - O’Bryant, Sid E.
AU - Verbeek, Marcel M.
AU - Dubois, Bruno
AU - Visser, Pieter Jelle
AU - Jellinger, Kurt A.
AU - Engelborghs, Sebastiaan
AU - Ramirez, Alfredo
AU - Parnetti, Lucilla
AU - Jack, Clifford R.
AU - Teunissen, Charlotte E.
AU - Hampel, Harald
AU - Lleó, Alberto
AU - Jessen, Frank
AU - Glodzik, Lidia
AU - de Leon, Mony J.
AU - Fagan, Anne M.
AU - Molinuevo, José Luis
AU - Jansen, Willemijn J.
AU - Winblad, Bengt
AU - Shaw, Leslie M.
AU - Andreasson, Ulf
AU - Otto, Markus
AU - Mollenhauer, Brit
AU - Wiltfang, Jens
AU - Turner, Martin R.
AU - Zerr, Inga
AU - Handels, Ron
AU - Thompson, Alexander G.
AU - Johansson, Gunilla
AU - Ermann, Natalia
AU - Trojanowski, John Q.
AU - Karaca, Ilker
AU - Wagner, Holger
AU - Oeckl, Patrick
AU - van Waalwijk van Doorn, Linda
AU - Bjerke, Maria
AU - Kapogiannis, Dimitrios
AU - Kuiperij, H. Bea
AU - Farotti, Lucia
AU - Li, Yi
AU - Gordon, Brian A.
AU - Epelbaum, Stéphane
AU - Vos, Stephanie J.B.
AU - Klijn, Catharina J.M.
AU - Van Nostrand, William E.
AU - Minguillon, Carolina
AU - Schmitz, Matthias
AU - Gallo, Carla
N1 - Funding Information: Inga Zerr is supported by Robert Koch Institute through funds from the Federal Ministry of Health (grant no. 1369-341) and DZNE. Funding Information: Markus Otto was supported by the grants from JPND network PreFrontAls (01ED1512), and the German Federal Ministry of Education and Research (FTLDc O1GI1007A). Funding Information: Mony de Leon has funding from the NIH AG022374, AG013616, AG012101, AG008051, and from the Cohen Veterans Bioscience Foundation. He has several imaging and CSF-based patents that are managed by New York University. Funding Information: Dimitrios Kapogiannis is supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. Funding Information: Harald Hampel is supported by the AXA Research Fund, the Fondation Université Pierre et Marie Curie and the Funding Information: Sid E. O’Bryant receives funding from the NIH/NIA under awards AG054073, AG051848 and from the Alzheimer’s Association. He has patents pending related to blood biomarkers in Alzheimer’s disease. He has served on an advisory board and received honoraria from Roche Diagnostics. He is a consultant to and owns stock in Cx Precision Medicine, Inc. Funding Information: Catharina Klijn has received a clinical established investigator grant of the Dutch Heart Foundation (No 2012T077) and an Aspasia grant from the Netherlands Organisation for Health Research and Development, ZonMw (015008048). Funding Information: John Q. Trojanowski is supported by the following grants from the National Institutes of Health: AG10124, AG17586, AG024904, and NS053488. Funding Information: Marcel M. Verbeek is funded by: the CAVIA project (nr. 733050202), which has been made possible by ZonMW (The CAVIA project is part of ‘Memorabel’, the research and innovation programme for dementia, as part of the Dutch national ‘Deltaplan for Dementia’: zonmw.nl/dementiaresearch’. The CAVIA project is a consortium of Radboudumc, LUMC, Erasmus MC, VUmc, ADX Neurosciences, Philips Healthcare, Stony Brook University and Massachusetts General Hospital); BIOMARKAPD research project within the EU Joint Programme – Neurodegenerative Disease (JPND, The project is supported through national funding organisations under the aegis of JPND (http://www.jpnd.eu). For the Netherlands, the Netherlands Organisation for Health Research and Development (ZonMw)); The Internationale Stichting Alzheimer Onderzoek (projects 12506 and 14502); American Alzheimer Association (project IIRG-10-173389). Funding Information: Anne M. Fagan is supported by NIH grants including P50AG005681, P01AG003991, P01AG026276 and UF01AG03243807. Dr. Fagan is on the Scientific Advisory Boards for Roche Diagnostics, IBL International and AbbVie and consults for Biogen, DiamiR, LabCorp and Araclon Biotech/Griffols. Funding Information: Research conducted by José Luis Molinuevo receives support by: the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD grant agreement n° 115952; the EU/ EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115736; the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AETIONOMY grant n° 115568; the EU JPND in Spain through the National Institute of Health Carlos III (AC14/00014) and European Regional Development Fund (ERDF): ‘a way to build Europe’; and ‘la Caixa’ Foundation. He is/has been a scientific consultant and/or attended scientific advisory boards of Roche Diagnostics, IBL, Raman Health, Biocross and Fujirebio Europe. Funding Information: This work was funded by Bundesministerium f?r Bildung und Forschung, Germany (BiomarkAPD [grant number 01ED1203D]; Kompetenznetz Demenzen [grant number 01GI0420]) Funding Information: This is an EU Joint Programme – Neurodegenerative Disease Research (JPND) project, supported through the funding organisations under the aegis of JPND (www.jpnd.eu). The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n° 115372, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This study has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420). Funding Information: Piotr Lewczuk is supported by funds from the Leading National Research Centre (KNOW), and grants for neurodegenerative diseases, Medical University of Białystok, Białystok, Poland, and received consultation and lectures honoraria from Innogenetics/Fujirebio Europe, IBL International, AJ Roboscreen, Beckman Coulter, Virion/Serion GmbH, and Roche. Funding Information: Henrik Zetterberg is a Walllenberg Academy Fellow and supported by grants from the Swedish and European Research Councils. Funding Information: Maria Bjerke and Sebastiaan Engelborghs are partially funded by: the University of Antwerp Research Fund; unrestrictive research grants from Janssen Pharmaceutica NV and ADx Neurosciences; the Flemish Government initiated Methusalem excellence grant (EWI, www.ewi-vlaanderen.be); the Flanders Impulse Program on Networks for Dementia Research (VIND); the Agency for Innovation by Science and Technology (IWT, www.iwt.be); and the Research Foundation Flanders (FWO, www.fwo.be). Funding Information: Jens Wiltfang is supported by an Ilídio Pinho professorship and iBiMED (UID/BIM/04501/2013), at the University of Aveiro. Funding Information: research leading to these results has received funding from the programme ‘Investissements d’avenir’ ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6). He serves as Senior Associate Editor for the journal Alzheimer’s & Dementia; he has been a scientific consultant and/or speaker and/or attended scientific advisory boards of Axovant, Anavex, Eli Lilly and company, GE Healthcare, Cytox Ltd, Jung Diagnostics GmbH, Roche, Biogen Idec, Takeda-Zinfandel, Oryzon Genomics, Qynapse, Merck, Sharp & Dohme (MSD); and receives research support from the Association for Alzheimer Research (Paris), Pierre and Marie Curie University (Paris), Pfizer & Avid (paid to institution); and has patent applications, but receives no royalties. Funding Information: This work was funded by Bundesministerium für Bildung und Forschung, Germany (BiomarkAPD [grant number 01ED1203D]; Kompetenznetz Demenzen [grant number 01GI0420]) and Innovative Medicines Initiative Joint Undertaking [grant number EMIF 115372]. Publisher Copyright: © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/5/19
Y1 - 2018/5/19
N2 - In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.
AB - In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.
KW - Alzheimer’s disease
KW - biomarkers
KW - cerebrospinal fluid
KW - consensus
KW - dementia
UR - http://www.scopus.com/inward/record.url?scp=85032381406&partnerID=8YFLogxK
U2 - 10.1080/15622975.2017.1375556
DO - 10.1080/15622975.2017.1375556
M3 - Review article
C2 - 29076399
AN - SCOPUS:85032381406
SN - 1562-2975
VL - 19
SP - 244
EP - 328
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 4
ER -